Clinical trial studies combination effect on small cell lung cancer

Dr. Anish Thomas, Staff Clinician in the Thoracic and GI Oncology Branch is conducting a clinical trial for small cell lung cancer (SCLC). SCLC is the most aggressive type of lung cancer and affects over 30,000 patients every year in the US alone. The trial will study the effect of the combination of a nanoparticle chemotherapy drug, CRLX101 and a DNA repair inhibitor, olaparib. Adults 18 and older with small cell lung cancer may be eligible. Contact Linda Sciuto, R.N. at (301) 451-9707 for more information.  View Trial Summary.

Summary Posted: 07/2016